Safety and Efficacy of Relestat Ophthalmic Solution 0.05% for Allergic Conjunctivitis in Korea

Allergan

Status: Completed

Conditions: Conjunctivitis, Allergic

Treatments: Drug: Relestat Ophthalmic Solution 0.05%

Study type: Observational

Funder types: Industry

Identifiers

NCT01987765

198027-A

Details and patient eligibility

About

This study is a Post-Marketing Surveillance study in Korea to evaluate the safety and efficacy of Relestat Ophthalmic Solution 0.05% in patients with allergic conjunctivitis who are treated with Relestat as standard of care in clinical practice.

Enrollment: 847 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with Allergic Conjunctivitis treated with Relestat Ophthalmic Solution in clinical practice.

Exclusion criteria

• None.

Trial design

847 participants in 1 patient group

Relestat Ophthalmic Solution 0.05%

Description:

Patients who are prescribed Relestat Ophthalmic Solution 0.05% as local standard of care in clinical practice.

Treatment:

Drug: Relestat Ophthalmic Solution 0.05%